Posted on Monday, November 25th, 2013 at 5:22 pm
Risperdal is prescription pharmaceutical drug primarily used to treat mental conditions such as schizophrenia. One of the side effects of taking Ripserdal can be the growth of breast tissue in males, referred to as gynecomastia. This condition can occur naturally in some males, but it is estimated that between 10 and 25% of the cases of gynecomastia result from taking pharmaceuticals. This traumatic condition has resulted in lawsuits against the massive Johnson & Johnson subsidiary Janssen.
Per the wikpedia entry with its extensive footnotes, this is the state of lawsuits relating Risperdal,
On 11 April 2012, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., were fined about $1.2 billion by an Arkansas judge. The jury found the companies had downplayed multiple risks associated with risperidone (Risperdal). The judge held that nearly 240,000 violations of the state’s Medicaid fraud law had been committed. Each violation carried a fine of $5,000. The companies were also fined $11 million for more than 4,500 violations of the state’s deceptive practices laws.
According to an online report from the Wall Street Journal on June 20, 2012, “Johnson & Johnson and the Justice Department are close to settling a protracted investigation into the company’s promotion of the antipsychotic Risperdal, for what would be one of the highest sums to date in a drug-marketing case. The sides are trying to wrap together a number of lawsuits, state investigations and other probes of alleged illegal marketing, and are discussing a payment of $1.5 billion or higher.”
In August 2012, Johnson & Johnson agreed to pay $181 million to 36 U.S. states in order to settle claims that it had promoted risperidone for non-approved uses including dementia, anger management, and anxiety.“
In 2012, Johnson & Johnson settled a lawsuit claiming that Risperdal caused hundreds of male patients to grow breast tissue. Additionally, Janssen and Johnson & Johnson face many claims that consumers were misled by both marketing and product packaging of Risperdal.” Accessed on 11/25/13 at http://en.wikipedia.org/wiki/Risperidone